| Literature DB >> 34943156 |
Thanusha Dhananji Abeywickrama1, Inoka Chinthana Perera1.
Abstract
Mycobacterium tuberculosis is a well-known pathogen due to the emergence of drug resistance associated with it, where transcriptional regulators play a key role in infection, colonization and persistence. The genome of M. tuberculosis encodes many transcriptional regulators, and here we report an in-depth in silico characterization of a GntR regulator: MoyR, a possible monooxygenase regulator. Homology modelling provided a reliable structure for MoyR, showing homology with a HutC regulator DasR from Streptomyces coelicolor. In silico physicochemical analysis revealed that MoyR is a cytoplasmic protein with higher thermal stability and higher pI. Four highly probable binding pockets were determined in MoyR and the druggability was higher in the orthosteric binding site consisting of three conserved critical residues: TYR179, ARG223 and GLU234. Two highly conserved leucine residues were identified in the effector-binding region of MoyR and other HutC homologues, suggesting that these two residues can be crucial for structure stability and oligomerization. Virtual screening of drug leads resulted in four drug-like compounds with greater affinity to MoyR with potential inhibitory effects for MoyR. Our findings support that this regulator protein can be valuable as a therapeutic target that can be used for developing drug leads.Entities:
Keywords: GntR/HutC transcriptional regulators; druggability; homology modelling; structure validation; virtual screening
Year: 2021 PMID: 34943156 PMCID: PMC8698889 DOI: 10.3390/biology10121241
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1Secondary structure prediction of HutC regulators and MoyR model. Sequence alignment of MoyR and HutC homologs. Conserved residues are highlighted in boxes and secondary structure elements are from the structure of NagR regulator from Bacillus subtilis.
Figure 2Structure Characteristics of MoyR. (A) Secondary structure of modeled MoyR monomer using PDBsum webserver. This consists of nine α-helices and ten β-sheets. (B) Analysis of consensus residues of c-terminal effector binding domain of HutC regulators including MoyR. WebLogo represents the relative frequency of nucleotides at corresponding positions.
Figure 3Genomic locus of moyR (Rv0792c). Most of the adjacent genes are uncharacterized and code for hypothetical proteins. The genes which can be directly regulated by MoyR protein are highlighted in green.
Figure 4Modeled structure of MoyR. (A) Modeled dimeric MoyR protein, each monomer is modeled on chain A and chain B of Moyo respectively. (B) Topology diagram of MoyR monomer. Secondary structure elements are displayed as arrows (β-sheets) and cylinders (α-helices). The DBD consist of α-helices, α1–α3 and β-sheets, β1–β2. Most of the α-helices (α5–α9) and β-sheets (β4–β10) are concentrated in the EBD where the linker segment between the DBD and EBD is highlighted in bold.
Figure 5Predicted binding pockets of MoyR. (A) Predicted allosites (1 and2) between the DBD-EBD region and the orthosites (3 and 4) in the EBD domain of the dimer. (B) Conserved residues of the orthosite in the EBD of a monomer, conserved residues in the β-strands coloured in blue and α-helix residues coloured in green.
Identified conserved residues in binding pockets of MoyR, DasR and NagR involve in effector binding. Highly conserved residues are in bold.
| MoyR. | DasR | NagR |
|---|---|---|
| ARG 141 | ARG 142 | ARG 133 |
| THR 177 | SER 175 | SER 165 |
|
|
|
|
| VAL 221 | LEU 219 | ILE 209 |
|
|
|
|
|
|
|
|
Estimated druggability of the predicted binding pockets of MoyR using CavityPlus and PockDrug servers. In ligandability Pred. Max pKd value greater than six suggests that all the cavities are suitable as binding sites. Drug score is calculated on the basis of the binding structure alone by using a desolvation-based free energy model.
| CavityPlus Server | PockDrug Server | ||
|---|---|---|---|
| Ligandability | Drug score | Druggability | |
| Cavity 1 | 9.31 | 3129 | 0.92 |
| Cavity 2 | 11.34 | 2694 | 0.93 |
| Cavity 3 | 11.35 | 1445 | 0.91 |
| Cavity 4 | 10.24 | 1014 | 0.94 |
Best four lead compounds with high affinity of binding with MoyR.
| Compound. | Molecular Formula | Binding Energy (kcal/mol) | Interacting Residues in Binding Pockets 3 and 4 |
|---|---|---|---|
| 3-(4-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl 3-(trifluoromethyl)benzene-1-sulfonate | C27H23 F3 N4 O4 | −11.1 | VAL113, PRO111, ILE100, VAL 97, VAL153, VAL236, HIS240, THR177, THR101, PHE 238, ARG 223 |
| N-[3-[3-[(phenylsulfonyl)amino]-5-(trifluoromethyl)benzyl]-5-(trifluoromethyl)phenyl]benzenesulfonamide | C27H20F6N2O4 S2 | −11 | ARG98, VAL221, VAL153, ALA155, VAL113, ARG141 |
| N’1-[3-(trifluoromethyl)benzoyl]-2-[2,6-dimethyl-4-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)phenoxy]ethanohydrazide | C27H23F3N4 O4 | −10.9 | PRO111, VAL113, VAL236, VAL153, ILE100, TYR179, ALA 173, HIS240, ARG223, GLU234, PHE238, GLU92 |
| CHEMBL3222137—name undefined | C29H27NO8 | −10.6 | VAL 221, HIS 195, VAL 97, VAL 153, VAL236, ILE100, ALA173, TYR179, THR101, GLN 112, VAL113 |